Cogent Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Cogent Biosciences
COGT Stock  USD 8.03  0.10  1.23%   
Cogent Biosciences financial statements provide useful quarterly and yearly information to potential Cogent Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cogent Biosciences financial statements helps investors assess Cogent Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cogent Biosciences' valuation are summarized below:
Gross Profit
-121.6 M
Market Capitalization
887 M
Enterprise Value Revenue
925.407
Earnings Share
(2.48)
Quarterly Revenue Growth
(1.00)
There are currently one hundred twenty fundamental signals for Cogent Biosciences that can be evaluated and compared over time across rivals. All traders should validate Cogent Biosciences' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 641.7 M in 2025. Enterprise Value is likely to gain to about 528.1 M in 2025

Cogent Biosciences Total Revenue

0.0

Check Cogent Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cogent Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 4.8 M or Selling General Administrative of 41.5 M, as well as many indicators such as Price To Sales Ratio of 12.32, Dividend Yield of 0.0 or PTB Ratio of 1.23. Cogent financial statements analysis is a perfect complement when working with Cogent Biosciences Valuation or Volatility modules.
  
Check out the analysis of Cogent Biosciences Correlation against competitors.
For more information on how to buy Cogent Stock please use our How to Invest in Cogent Biosciences guide.

Cogent Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding96.2 M91.6 M28.1 M
Slightly volatile
Total Assets186.6 M360.5 M147.4 M
Slightly volatile
Other Current Liabilities31.5 M30 M8.3 M
Slightly volatile
Total Current Liabilities46.1 M43.9 M18.5 M
Slightly volatile
Total Stockholder Equity156.1 M296.5 M118.9 M
Slightly volatile
Property Plant And Equipment Net36.6 M34.9 M11.8 M
Slightly volatile
Current Deferred Revenue31 M29.5 M10.5 M
Slightly volatile
Accounts Payable12.9 M12.3 M3.9 M
Slightly volatile
Cash112.4 M61.2 M77.5 M
Slightly volatile
Non Current Assets Total51.5 M49.1 M16 M
Slightly volatile
Non Currrent Assets Other2.8 M5.6 M2.3 M
Slightly volatile
Cash And Short Term Investments166.7 M305.6 M131 M
Slightly volatile
Common Stock Total Equity84.5 K80.5 K32.6 K
Slightly volatile
Liabilities And Stockholders Equity186.6 M360.5 M147.4 M
Slightly volatile
Non Current Liabilities Total21.1 M20.1 M12.3 M
Very volatile
Other Current Assets3.4 M5.8 M2.2 M
Slightly volatile
Other Stockholder Equity967.3 M921.2 M265.3 M
Slightly volatile
Total Liabilities67.2 M64 M30.8 M
Slightly volatile
Property Plant And Equipment Gross41.1 M39.1 M12.7 M
Slightly volatile
Total Current Assets170.1 M311.4 M133.6 M
Slightly volatile
Short Term Debt3.1 M1.6 M2.1 M
Slightly volatile
Common Stock103.8 K98.9 K35.9 K
Slightly volatile
Inventory60 K67.5 K73.6 K
Slightly volatile
Net Working Capital160.7 M267.5 M104.3 M
Slightly volatile
Capital Stock59.1 M69.1 M28.2 M
Slightly volatile
Short and Long Term Debt Total11.6 M21.7 M8.8 M
Slightly volatile
Net Tangible Assets130.4 M218.4 M81.2 M
Slightly volatile
Other Assets4.8 M5.5 M3 M
Slightly volatile
Capital Lease Obligations11.6 M21.7 M8.8 M
Slightly volatile
Property Plant Equipment4.3 M7 M6.6 M
Slightly volatile
Capital Surpluse485.2 M691.3 M395.3 M
Slightly volatile
Preferred Stock Total Equity69.9 M59.2 M97.9 M
Slightly volatile

Cogent Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.7 M2.6 M1.2 M
Slightly volatile
Selling General Administrative41.5 M39.5 M13.8 M
Slightly volatile
Other Operating Expenses251.3 M239.3 M76.9 M
Slightly volatile
Research Development205.5 M195.7 M62.3 M
Slightly volatile
Total Operating Expenses251.3 M239.3 M76.9 M
Slightly volatile
Net Interest Income13.7 M13 M2.9 M
Slightly volatile
Interest Income13.7 M13 M2.9 M
Slightly volatile
Total Other Income Expense Net19 M18.1 M4.8 M
Slightly volatile
Reconciled Depreciation2.2 M4.3 M1.8 M
Slightly volatile
Cost Of Revenue2.1 M4.1 M1 M
Slightly volatile
Non Operating Income Net Other6.7 M8.7 M7.2 M
Pretty Stable
Selling And Marketing Expenses27.5 M30.9 M33.7 M
Slightly volatile

Cogent Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation37 M35.2 M9.3 M
Slightly volatile
Begin Period Cash Flow106.1 M162.3 M72.6 M
Slightly volatile
Depreciation4.3 M4.1 M1.5 M
Slightly volatile
Capital Expenditures2.3 M3.2 M2.1 M
Pretty Stable
End Period Cash Flow111.8 M61.2 M96.2 M
Pretty Stable
Issuance Of Capital Stock122 M186.1 M96.7 M
Slightly volatile
Change To Netincome21.1 M21.1 M10.3 M
Slightly volatile
Sale Purchase Of Stock1.4 M1.5 M86 M
Slightly volatile
Change Receivables1.6 M1.8 M2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio12.3218.1815.4447
Slightly volatile
PTB Ratio1.231.641.3168
Slightly volatile
Days Sales Outstanding35.2729.237.1506
Pretty Stable
Book Value Per Share3.543.728.7135
Slightly volatile
Stock Based Compensation To Revenue0.720.690.3592
Slightly volatile
Capex To Depreciation0.850.96.1954
Slightly volatile
PB Ratio1.231.641.3168
Slightly volatile
Payables Turnover0.230.30.1305
Slightly volatile
Sales General And Administrative To Revenue2.091.991.2978
Slightly volatile
Research And Ddevelopement To Revenue8.728.315.0389
Slightly volatile
Capex To Revenue0.00160.00170.2939
Slightly volatile
Cash Per Share3.643.8410.6407
Slightly volatile
Days Payables Outstanding1.2 K1.2 K18 K
Slightly volatile
Net Debt To EBITDA0.180.196.3644
Slightly volatile
Current Ratio7.056.389.6989
Slightly volatile
Tangible Book Value Per Share3.543.728.7135
Slightly volatile
Receivables Turnover7.0610.129.8201
Very volatile
Graham Number25.7115.2521.1276
Pretty Stable
Shareholders Equity Per Share3.543.728.7135
Slightly volatile
Debt To Equity0.08290.08410.1408
Slightly volatile
Capex Per Share0.03830.04040.1965
Slightly volatile
Graham Net Net2.883.037.9393
Slightly volatile
Revenue Per Share1.060.640.8958
Pretty Stable
Interest Debt Per Share0.440.270.6135
Slightly volatile
Debt To Assets0.0620.06920.0945
Slightly volatile
Operating Cycle35.2729.237.1506
Pretty Stable
Price Book Value Ratio1.231.641.3168
Slightly volatile
Days Of Payables Outstanding1.2 K1.2 K18 K
Slightly volatile
Ebt Per Ebit1.051.060.9641
Slightly volatile
Company Equity Multiplier1.471.41.3596
Pretty Stable
Total Debt To Capitalization0.07380.07840.1202
Slightly volatile
Debt Equity Ratio0.08290.08410.1408
Slightly volatile
Quick Ratio7.056.389.6985
Slightly volatile
Net Income Per E B T0.750.850.9302
Slightly volatile
Cash Ratio1.521.67.991
Slightly volatile
Days Of Sales Outstanding35.2729.237.1506
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio0.820.920.9644
Pretty Stable
Price To Book Ratio1.231.641.3168
Slightly volatile
Fixed Asset Turnover1.661.491.6727
Slightly volatile
Debt Ratio0.0620.06920.0945
Slightly volatile
Price Sales Ratio12.3218.1815.4447
Slightly volatile
Asset Turnover0.02680.02820.0745
Very volatile
Gross Profit Margin1.11.151.0136
Slightly volatile
Price Fair Value1.231.641.3168
Slightly volatile

Cogent Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap641.7 M611.1 M231.4 M
Slightly volatile

Cogent Fundamental Market Drivers

Cash And Short Term Investments265.7 M

Cogent Upcoming Events

12th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
12th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Cogent Biosciences Financial Statements

Cogent Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Cogent Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Cogent Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Cogent Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue29.5 M31 M
Cost Of Revenue4.1 M2.1 M
Stock Based Compensation To Revenue 0.69  0.72 
Sales General And Administrative To Revenue 1.99  2.09 
Research And Ddevelopement To Revenue 8.31  8.72 
Revenue Per Share 0.64  1.06 
Ebit Per Revenue(12.01)(11.41)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Cogent Stock Analysis

When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY